News
NICE rejects J&J's prostate cancer drug Erleada in initial g...
NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance.
